Only 1 to 2 pharmaceutical research projects in100 culminate in pharmaceuticals! Oncodesign has responded to this situation bydeveloping a unique technological platform designed to speed up the discoveryof new oncology drugs by leading pharmaceutical companies, thereby halvingtheir research time and reducing cost by a factor of four... while boostingtheir success rate four times1.
The use of cutting-edge tools and expertisecombining pharmacology, medicinal chemistry and medical imaging allowsOncodesign to identify, as far upstream as possible, the therapeutic value ofeach molecule and its potential to become an effective drug. Instead of lookingfirst for new therapeutic targets, Oncodesign uses its proprietary library of 6,000 highly qualified and selective kinase inhibitors, developed incollaboration with Johnson&Johnson, to explore new targeted kinases.This strategy optimizes the upstream research phases preceding clinical development, significantly shortening the time needed for completion.
With over 3,000 molecules tested in 19 years and more than 500 clients including the largest pharmaceutical companies in the world, Oncodesign offers unique experience with experimental anti-cancer therapies. From the outset, Oncodesign focused its research on the most promising of these therapies: kinase inhibitors.
Kinase inhibitors are molecules with an estimated market value of over 30 bn euros in 2016 and account for almost 25% of the R&D investment of the global pharmaceuticals industry3. Their importance lies in the fact that they block the action of deregulated kinases. Kinases are enzymes that regulate the organism. Deregulated kinases are responsible for more than 400 diseases, including a great many cancers.
In contrast with other kinase inhibitors on the market, Oncodesign develops a new generation of specifically targeted kinase inhibitors with minimal side-effects for patients. Oncodesign's technology permits the development of small, but very specific and rigid macrocyclic molecules, thanks to a three-dimensional shape specifically designed to target the inhibition of the kinase responsible for a particular disease. Oncodesign focuses on several kinases with a high therapeutic potential for oncology (ovarian cancer, pancreatic cancer, glioblastoma) and other indications (Parkinson's disease, Crohn's disease, polyarthritis, psoriasis).
Oncodesign has already signed important partnership deals for its new generation kinase inhibitors, including partnerships with 3 leading global pharmaceutical companies: Sanofi, Ipsen and UCB. In total, these partnerships can be expected to generate medium to long term revenue for Oncodesign, excluding royalties, of up to € 350 m, both up front to finance research and on achievement of regulatory and commercial milestones.
Set up in 1995, Oncodesign currently has a workforce of 95 employees. Growth is underpinned by a balanced, pragmatic and efficient business model.
The majority of Oncodesign's capital remains in the hands of its founders, seamlessly aligning management and shareholder interests. This is genuine entrepreneurial feat and a rare occurrence in the biotechnology sector.
 Company estimates
 Market for kinase inhibitors in 2016 (sources: BCC Research 2012)
 Sources: The Druggable Genome (A.L. Hopkins and C.R. Groom, Nature Reviews Drug Discovery,Vol. 1, 727-730), Global Industry Analysts 2012